Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension?
In April 2008, a panel was convened to discuss the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in the treatment of hypertension and the possible added benefit of using these agents together. The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine at Yale University School of Medicine, and included Clive Rosendorff, MD, PhD, Professor of Medicine at Mount Sinai School of Medicine and William B. White, MD, Division Chief, Hypertension and Clinical Pharmacology and Professor, Calhoun Cardiology Center at the University of Connecticut Health Center, Farmington.
Marvin
M
Moser
Clive
C
Rosendorff
William B
WB
White
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors